Neurology
-
Randomized Controlled Trial Multicenter Study Clinical Trial
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
To determine the safety and efficacy of botulinum toxin type B (BoNT/B) in patients with cervical dystonia (CD). ⋯ Botulinum toxin type B (NeuroBloc) is safe and efficacious at 5,000 U and 10,000 U for the management of patients with cervical dystonia.
-
Randomized Controlled Trial Clinical Trial
The effect of vigabatrin (gamma-vinyl GABA) on cerebral blood flow and metabolism.
To investigate the effect of vigabatrin (VGB; gamma-vinyl gamma-aminobutyric acid [GABA]), a selective irreversible GABA-transaminase inhibitor, on cerebral metabolic rate for glucose (CMRGlc) and cerebral blood flow (CBF) measured with 18F-fluorodeoxyglucose (FDG) PET and 15O water PET. ⋯ Vigabatrin (VGB) causes mild reductions in both cerebral blood flow (CBF) and cerebral metabolic rate for glucose (CMRGlc) in contrast to other drugs such as barbiturates, which are direct agonists at the gamma-aminobutyric acid-benzodiazepine receptor complex. Conventional AEDs depress CBF and CMRGlc to a greater degree than does VGB. The relatively mild reduction could be due to pre- as well as postsynaptic effects or a use-dependent mechanism.
-
Randomized Controlled Trial Clinical Trial
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
To determine the safety and efficacy of botulinum toxin type B (BoNT/B) in patients with type A-resistant cervical dystonia (CD). ⋯ Botulinum toxin type B (BoNT/B) (NeuroBloc) is safe and efficacious for the management of patients with type A-resistant cervical dystonia with an estimated duration of treatment effect of 12 to 16 weeks.